Jazz Pharmaceuticals plc (JAZZ)
A+
Pipeline Grade
Financial Position (from SEC Filings)
$1,844.3M
Cash & Equivalents
$408.2M
Quarterly Burn Rate
$14,905M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (4 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
FLUVOXAMINE MALEATE
LUVOX |
APPROVED | Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL), Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, Acute Myeloid Leukaemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia (AML) in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute-graft-versus-host Disease, Adenovirus, Advanced Cancer, Advanced Solid Tumor, Alternating Hemiplegia of Childhood, Anaplastic Large Cell Lymphoma, Anxiety, Anxiety Disorder, Autism Spectrum Disorder, Binge-Eating Disorder, Bone Marrow Transplant Complications, Brain Tumor, Brain Tumor, Recurrent, Breast Cancer, Burkitt Lymphoma, Cannabis, Caregivers, Coronary Artery Stenosis, Cytomegalovirus Infection, Diffuse Intrinsic Pontine Glioma, Diffuse Large Cell Lymphoma, Dravet Syndrome, Effects of Sativex on ECG, Electrical Status Epilepticus of Slow-Wave Sleep, Epilepsy, Evaluation of Pharmacokinetics of Sativex in the Absence and Presence o |
|
LURBINECTEDIN
ZEPZELCA |
APPROVED | — |
|
CALCIUM OXYBATE, MAGNESIUM OXYBATE, POTASSIUM OXYBATE, SODIUM OXYBATE
XYWAV |
APPROVED | — |
|
CLOZAPINE
FAZACLO ODT |
NDA | — |
Upcoming Catalysts
No upcoming catalysts detected for this company.